Marengo Presents Interim Phase 2 STARt-002 Results for First-in-Class Selective T-Cell Agonist Invikafusp Alfa Plus Sacituzumab Govitecan Across Two Metastatic Breast Cancer Cohorts in Oral Presentation at SITC 2026

Marengo Therapeutics announced interim Phase 1b/2 results from the STARt-002 trial combining invikafusp alfa, a first-in-class selective T-cell agonist, with sacituzumab govitecan for metastatic breast cancer. The combination showed 71% reduction in target lesions, confirmed complete responses in both triple-negative and HR-positive/HER2-negative cohorts, and 74% disease control overall with a manageable safety profile.